论文部分内容阅读
目的：比较尼美舒利和萘普生治疗骨关节炎的疗效和安全性。方法：采用随机、双盲或单盲、多中心、对照研究方法。尼美舒利１００例（男性４１例，女性５９例，年龄５４±ｓ１０ａ），萘普生６８例（男性２９例，女性３９例，年龄５３±１２ａ）。尼美舒利口服１００ｍｇ，ｂｉｄ；萘普生口服２５０ｍｇ，ｂｉｄ，疗程２ｗｋ。结果：尼美舒利的总有效率为８３％，萘普生的总有效率为７５％（Ｐ＜０．０５）。不良反应发生率分别为２３％和３２％（Ｐ＞０．０５），以胃肠反应为主。结论：尼美舒利对骨关节炎治疗作用优于萘普生，不良反应发生率与萘普生相近。
Objective: To compare the efficacy and safety of nimesulide and naproxen in the treatment of osteoarthritis. Methods: A randomized, double-blind or single-blind, multicenter, controlled study was used. Nimesulide 100 (41 males, 59 females, age 54 ± s10a), naproxen 68 (29 males, 39 females, age 53 ± 12a). Nimesulide oral 100mg, bid; naproxen oral 250mg, bid, treatment 2wk. Results: The total effective rate of nimesulide was 83% and the total effective rate of naproxen was 75% (P <0.05). The incidence of adverse reactions were 23% and 32% (P> 0.05), mainly gastrointestinal reactions. Conclusion: Nimesulide is superior to naproxen on the treatment of osteoarthritis. The incidence of adverse reactions is similar to that of naproxen.